Skip to main content
Premium Trial:

Request an Annual Quote

Talis Biomedical: Melissa Gilliam

Talis Biomedical, a developer of molecular point-of-care infectious disease diagnostic tests, has appointed Melissa Gilliam to its board of directors. Gilliam is the Ellen H. Block Professor of Health Justice and vice provost of the University of Chicago. She is also a professor of obstetric and gynecology and professor of pediatrics at the university, and is the founder and director of the Center for Interdisciplinary Inquiry and Innovation in Sexual and Reproductive Health. Gilliam holds a BA in English from Yale University, an MA in philosophy and politics from Oxford University, an MD from Harvard Medical School, and an MPH in epidemiology and biostatistics from the University of Illinois at Chicago. She completed her residency in obstetrics and gynecology at Northwestern University.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.